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Risperidone is an atypical antipsychotic acting mainly as a dopamine D2 and serotonin 5-HT2 receptors 
antagonist prescribed in the treatment of schizophrenia and various affective disorders. Risperidone 
has been reported to be associated with weight gain, panreatitis and type 2 diabetes mellitus. Various 
mechanisms of risperidone-induced toxicities have been reported but the histology of tissues especially 
pancreas has never been studied. Therefore, the current study was designed to elucidate the toxic effects 
of chronic administration of risperidone on pancreas, liver and kidneys. Animals (rats) of either gender 
were divided into two groups, the risperidone and control groups. Risperidone was administered in 
a dose of 2.5 mg/kg/d for three weeks. The controls received acidified saline only. Both the groups 
received restricted diet (20 g/12 h). The body weight and level of random blood sugar (RBS) were 
measured on a weekly basis. The levels of lipase and amylase were determined at the conclusion of the 
experiment. At the end of the experiment, the tissues were dissected out for histopathological evaluation. 
Risperidone showed no weight gain, hyperglycemia or rise in the level of lipase (P> 0.05); however, the 
level of amylase was raised (***P<0.05). Histological examination under light microscope showed no 
hepatotoxicity, nephrotoxicity but did show damage to the pancreas. The findings of this study indicated 
that the incidence of adverse effects associated with risperidone could be prevented/alleviated/delayed 
by allowing restricted diet. 
Keywords: Risperidone/antipsychotics/oral administration/effects. Histopathology. D2 antagonist. 
Pancreas.
INTRODUCTION
Risperidone is an atypical antipsychotic which 
is used in the treatment of schizophrenia and other 
psychiatric problems. It has got D2 and 5 HT2 antagonistic 
properties which, on one hand, render it an effective 
antipsychotic drug but, on the other hand, result in 
unwanted effects including hyperphagia, weight gain, 
hyperglycemia and pancreatitis (Koller et al., 2003a; 
Pouzet et al., 2003; Wirshing et al., 1998). Weight gain 
is believed to be due to hyperphagia which, in turn, due 
to its anti-dopaminergic, anti-serotonergic properties 
and H1 blocking activities. Several researchers have 
postulated dietary interventions and control on calories 
to prevent weight gain and subsequent untoward effects 
like dyslipidemia, hyperglycemia and pancreatitis 
(Fountaine et al., 2010; Gohlke et al., 2012). Food and 
Drug Administration’s MedWatch Surveillance System 
as well as published reports have indicated one hundred 
ninety-two patients with pancreatitis receiving one or the 
other antipsychotic, with 16 % due to risperidone only 
(Koller et al., 2003a; Koller et al., 2003b).
Halici and his colleagues have reported that i/p 
administration of risperidone (0.5 and 1mg/kg) for 6 
weeks did not affect the architecture of liver of rats (Halici 
et al., 2008). They while using both light and electron 
microscope, report no significant changes in total liver 
cells count and numerical density of liver of risperidone 
treated rats and placebo. Stereological results were 
confirmed from structural and ultrastructural examination 
of liver and concluded that neither low nor higher doses 
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of risperidone proved hepatotoxic (Halici et al., 2008). 
Nephrotoxicity with chronic administration (6 weeks) of 
risperidone (0.5 and 1 mg/kg/d) has been reported with 
postulation that it was due to oxidative stress (Mustafa 
et al., 2012). It has been reported that risperidone causes 
elevation of amylase and lipase (Koller et al., 2003a), 
but there are rare reports giving a clear idea about its 
toxic effects on the architecture of pancreas. Dietary and 
pharmacological interventions have been recommended 
to lessen the APDs-associated alarming events (Gohlke et 
al., 2012), but have never been reported.
We are aimed, in this study, to assess the effects of 
risperidone (2.5 mg/kg/d) after 21 days oral administration, 
on selected tissues, including pancreas, liver and kidneys, 
and on blood glucose, body weight, amylase and lipase, 
while allowing restricted quantity of food (20 g/12 h), with 
free access to water.
It is relevant to mention that risperidone is available 
as tablets and syrups in conventional formulations in 
the market while its sustained release and injectable 
formulations are under investigations (Badshah et al., 
2011; Fleischhacker et al., 2003; Siafaka et al., 2015). 
MATERIAL AND METHODS 
Animals
Sprague-dawley rats were bred in the animal 
house, Department of Pharmacy, University of Peshawar. 
Total 14 animals of either sex, weighing 160 to 300 g, 
were housed in plastic cages at a control climate (19 
to 23 0C). The rats were maintained on 12 h reversed 
light-dark cycle (light on between 21:00 and 9:00 h), 
started 2 weeks before the commencement of dosing. 
The animals were then equally stratified into 2 groups, 
each comprising of 7 animals, one for each drug and the 
control. All animals were having free access to water and 
restricted quantity of food (20 g/12 h/animal) (Pouzet et 
al., 2003). All the procedures were approved from the 
ethical committee (approval number, 02/EC-14/Pharm), 
Department of Pharmacy, University of Peshawar 
and were in strict accordance with Animals Scientific 
Procedures Act, 1986, UK.
Procedures 
Drugs treatment 
The animals were kept fasted for 24 hours before 
the first dose was administered. Risperidone was 
generously gifted by Global Pharmaceutical Company 
Private Islamabad, Pakistan. It was used orally in a dose 
of 2.5 mg/kg/d based on the previous data available 
(Terry Jr et al., 2003). Risperidone was formulated by 
dissolving in small quantity of 0.1 N acetic acid followed 
by volume make-up with normal saline in a ratio of 
1 to 100. Controls were administered normal saline 
in a volume based on body weight (not greater than 
5 mL/kg/d). Both of the solutions were administered 
orally by oral gavage method. Fresh solutions were 
prepared each day (Terry et al., 2003).
Body weight measurement 
The animals were weighed before the administration 
of the first dose as well as weekly before the administration 
of next newly calculated dose. 
Random Blood Sugar (RBS)
Randome Blood Glucose (RBS) was measured 
weekly, using Abbot Glucometer.
Amylase and lipase levels 
Both amylase and lipase were determined at the 
end of the experiment. Animals were euthanized using 
ketamine, (Ali et al., 2013; Shah et al., 2015), in order 
to minimize stress and pain to the animals during blood 
collection. The blood was collected by cardiac puncture, 
centrifuged, and the serum collected was stored at 4-8 
0C till analyzed. The serum collected was analyzed 
for levels of amylase and lipase using single beam 
spectrophotometer (Unico 1100RS). The amylase and 
lipase kits (Cat. No. LI 188, 20 x 2.5 ml), were purchased 
from Randox Laboratories Limited, UK. 
Hematoxylin and Eosin (H & E) Staining 
The animals were euthanized, selected tissues 
including pancreas, liver and kidneys were isolated, 
washed with Phosphate Buffered Saline (PBS), sliced into 
small pieces and fixed for not less than 6 hours. The fixed 
samples of tissues were further sliced into small pieces 
of 3-5 mm and embedded separately in paraffin blocks. 
These blocks were sectioned using microtome (SLEE 
MAINZ, CUT 5062). Sections of different sizes (3 µ, 5 µ 
and 10 µ) were taken and stained using H & E staining 
technique. The stains such obtained were analyzed under 
light microscope (LABOMED LX400) equipped with 
camera (iVu 3100). The images obtained were labeled, 
saved and interpreted for any drug induced changes (Ali 
et al., 2013; Shah et al., 2015).
STATISTICAL ANALYSIS
All statistical analysis was carried out using graph 
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pad prism version 5 (Graph Pad Software Inc. San 
Diego CA, USA) applying 1-way ANOVA (Bonferroni’s 
Multiple Comparison Test) or unpaired t-test where 
applicable. Data were expressed as mean± standard error 
of the mean (SEM). P < 0.05 was considered as statistically 
significant.
RESULTS 
Percent weight gain
Risperidone showed no significant change in body 
weight (not significant), as compared to normal saline, as 
depicted in Figure 1.
Random Blood Sugar (RBS)
Random Blood Sugar (RBS) was determined weekly 
using Abbott Glucometer. Risperidone did not show 
significant rise in blood sugar (not significant). The results 
are shown in Figure 2.
Pancreatic Functions Tests (PFTs) 
Risperidone was tested for its effects on amylase 
and lipase applying unpaired t-test. Risperidone showed 
significant rise in the level of amylase (***P<0.001) but 
lipase remained unaffected. The results are shown in 
Figures 3 and 4.
FIGURE 1 - Effect of risperidone on percent weight gain: Three 
weeks treatment of rats treated with risperidone (2.5 mg/kg/d) 
orally showing no significant rise in percent weight (ANOVA 
followed by Bonferroni’s Multiple Comparison Test, not 
significant). 
FIGURE 2 - Effect of risperidone on RBS: Three weeks 
treatment of rats treated with risperidone (2.5 mg/kg/d) orally 
showing no significant rise in random blood sugar (RBS) 
(mg/dL) (ANOVA followed by Bonferroni’s Multiple 
Comparison Test, not significant).
FIGURE 3 - Effect of Risperidone (2.5 mg/kg/d) on amylase: 
Three weeks oral treatment of rats exhibited significant increase 
in amylase level (U/L) in risperidone treated group as compared 
to control (***P<0.001) (unpaired t-test).
HISTOLOGICAL STUDY
Effect on pancreas
The islets of Langerhans were shown clearly 
packed and compacted in the controls whereas the islets 
of Langerhans in the pancreas of risperidone treated rats 
seemed scattered showing derangement of pancreatic islets 
of Langerhans, as shown in Figures 5 and 6.
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Effect on kidneys
As shown in Figures 7 to 11, the glomeruli with intact 
structure and blood perfusion were identified in the kidneys 
of rats. Bowman’s capsules with intact endothelium were 
observed both in controls and risperidone treated rats. No 
prominent architectural damage could be seen.
Effect on liver
The liver of rats of both groups seemed unaffected. 
Central vein and hepatic plates radiating outwards were seen 
normal in controls and risperidone treated rats. Risperidone 
FIGURE 4 - Effect of Risperidone (2.5 mg/kg/d) on lipase: Three 
weeks oral treatment of rats exhibited no significant increase in 
lipase level (U/L) in risperidone treated group as compared to 
control (not significant) (unpaired t-test).
FIGURE 5 - Effect of normal saline on the pancreas of rats 
(H & E, 400x, 5 µ): Representative image of pancreas of rats 
treated with normal saline orally for three weeks showing islets 
of Langerhans, packed as compact and intact glandular mass. 
FIGURE 6 - Risperidone-induced histopathological changes in 
pancreas (H & E, 400x, 5 µ): Representative image of pancreas 
of rats treated with risperidone (2.5 mg/kg/d) orally for three 
weeks showing derangement of islets of Langerhans, lacking 
compaction of glandular cells as compared to rats treated with 
normal saline.
FIGURE 7 - Effect of normal saline on the kidneys of rats 
(H & E, 100x, 5 µ): Representative image of kidney of rats 
treated with normal saline orally for three weeks showing thin 
walled endothelium of Bowman’s capsule, glomeruli with intact 
cellular borders, blood perfusion and convoluted tubules. 
FIGURE 8 - Effect of normal saline on the kidneys of rats 
(H & E, 400x, 5 µ): Representative image of kidney of rats 
treated with normal saline orally for three weeks showing thin 
walled endothelium of Bowman’s capsule, glomerulus with 
intact cellular borders, blood perfusion and convoluted tubules.
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FIGURE 9 - Effect of risperidone on the kidneys of rats 
(2.5 mg/kg/d) (H & E, 100x,5 µ): Representative image of 
kidney of rats treated with risperidone (2.5 mg/kg/d) orally for 
three weeks showing thin walled endothelium of Bowman’s 
capsule, glomeruli with intact cellular borders, blood perfusion 
and convoluted tubules. 
FIGURE 10 - Effect of risperidone on the kidneys of rats 
(2.5 mg/kg/d) (H & E, 400x,5 µ): Representative image of kidney 
of rats treated with risperidone orally for three weeks showing 
thin walled endothelium of Bowman’s capsule, glomeruli with 
intact cellular borders, blood perfusion and convoluted tubules. 
FIGURE 11 - Effect of risperidone on the kidneys of rats 
(2.5 mg/kg/d) (H & E, 100x, 5 µ): Representative image of 
kidney of rat treated with risperidone orally for three weeks 
showing intact cortical region of the kidney without any drug-
induced architectural insult.
treatment did not insult the parenchyma of liver showing 
normal architecture, as shown in Figures 12 and 13.
DISCUSSION 
Risperidone has been classed among the most 
effective and fundamental tools in treating schizophrenia 
and other related disorders, but body weight gain (Baptista 
et al., 2004), hyperglycemia (Baptista et al., 2004), 
pancreatitis (Koller et al., 2003a) and nephrotoxicity 
(Mustafa et al., 2012) have been postulated among the 
major adverse drug reactions associated with risperidone. 
The mechanism of these adverse events has, however, 
still not been unveiled successfully. Excessive food 
FIGURE 12 - Effect of risperidone on the liver of rats (H & E, 
100x, 3 µ): Representative images of liver of rats treated 
with normal saline orally for three weeks showing no hepatic 
architectural changes. 
intake (Baptista et al., 2004), H1 antagonism (Baptista 
et al., 2004) and insulin resistance (Baptista et al., 2004) 
have been labeled as one of the causes of weight gain 
and hyperglycemia. We therefore modified the model 
and used diet restriction to exclude the involvement of 
excessive food intake in inducing these alarming events, 
and noticed no weight gain and hyperglycemia in the 
prescribed duration of treatment. In a placebo controlled, 
double blind crossover study, Fountain and his colleagues 
have reported weight gain in human healthy volunteers 
which was associated with excessive food intake and 
increased resting energy expenditure in antipsychotic 
treated rats as compared to placebo (Fountaine et al., 
2010). In our study model, the least significant effect on 
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body weight and subsequent expected elevation in blood 
glucose is supposed to be due to access to restricted diet 
in risperidone treated rats. 
The level of amylase was, however, elevated, while 
lipase remained unaffected, in our study. Contrary to this, 
Yamaguchi and his co-workers have reported ameliorative 
effect of risperidone on pancreatitis. They reported that 
risperidone significantly attenuated serum interleukin levels, 
amylase, lipase, platelets count, histological changes and 
mortality rate in choline-deficient, ethionine-supplimented 
diet-induced pancreatitis in mice (Yamaguchi et al., 2009). 
Random blood sugar can be easily tested by puncturing 
the tip of the tail which is not practicable for amylase and 
lipase for which minimum of 1 ml blood is required each 
time and thus practically not possible in such small animals. 
This was the reason that both of the enzymes were tested 
at the conclusion of the experiment. The reason of these 
inconsistent findings could be; (1). Use of both genders 
though it is known that female rats are more sensitive than 
male (Baptista et al., 2004) (2). Use of restricted diet (20 
g/24h) (3). Single daily dosing is not sufficient to induce 
these pathologies (3). Risperidone might have lost/reduced 
its potency in solution form.
This is novelty of the study that the biochemistry 
of pancreas has been correlated with its histology. In 
most of the studies, either amylase or lipase has been 
studied but we have compared histopathology of pancreas 
with the enzymes released by it i.e. amylase and lipase. 
Derangement of islets of Langerhans lacking compaction 
of glandular cells was observed in risperidone treated rats 
which is supported by elevation in the level of amylase. 
Although hyperglycemia has not been observed, the 
histopathological changes in the architecture of pancreas 
and elevation of amylase warn about the induction 
of diabetes if the treatment is continued for a longer 
period of time. No studies have been found reporting 
the histopathological impact of risperidone on pancreas 
supported by biochemical assessment.
We did not notice any pathological changes in the 
architecture of kidneys and liver which is in line with 
previous studies (Halici et al., 2009; Mustafa et al., 2012). 
The liver of rats of both the groups seemed unaffected. 
Central vein and hepatic plates radiating outwards were seen 
normal in controls and risperidone treated rats. Risperidone 
treatment did not insult the parenchyma of liver showing 
normal architecture. Similarly, glomeruli with intact 
structure and blood perfusion were identified in the kidneys 
of rats. Bowman’s capsule with intact endothelium was 
observed both in controls and risperidone treated rats. No 
prominent architectural damage could be observed.
The glucose-stimulated cholinergic pathway of 
insulin release is regulated by muscarinic M3 receptors 
which has been reported to be interfered by atypical 
antipsychotics including risperidone (Weston-Green, 
Huang, Deng, 2013). Our study supports this finding since 
risperidone and our previous findings about olanzapine 
showed that these drugs directly damage pancreatic islets 
(Shah et al., 2015). However, risperidone remains safe to 
both liver and kidneys. 
CONCLUSIONS 
Three weeks oral administration of risperidone 
(2.5 mg/d) in rats did not cause hyperglycemia, weight 
gain, architectural insult to kidneys and liver except 
derangement of beta cells of Langerhan in pancreas in 
our set model.
LIMITATIONS 
The histopathology of kidney and liver was not 
correlated with renal and liver function tests respectively. 
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FIGURE 13 - Effect of risperidone on the liver of rats (H & E, 
100x, 3 µ): Representative images of liver of rats treated with 
risperidone (2.5 mg/kg/d orally for three weeks showing no 
hepatic architectural changes as compared to normal saline 
treated rats.
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